/
ABCL
$5.94+$0.30 (+5.57%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.7B
305M shares
52-week range
$2.75 – $8.44
56% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-10.13
AbCellera Biologics Inc. Common Shares
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
www.abcellera.com- Employees
- 562
- IPO / List date
- Dec 11, 2020
- HQ
- VANCOUVER, A1
Held by traders on TradeandTell
No one on the platform currently holds ABCL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,510,629 | $5.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ABCL yet.
